Matthias Alder - 15 Jul 2022 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Chief Operating Officer
Signature
/s/ Jason Minio, Attorney-in-Fact
Issuer symbol
GANX
Transactions as of
15 Jul 2022
Net transactions value
$0
Form type
4
Filing time
19 Jul 2022, 16:36:48 UTC
Previous filing
28 Dec 2021
Next filing
22 Sep 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Employee Stock Option (right to buy) Award $0 +79,200 $0.000000 79,200 15 Jul 2022 Common Stock 79,200 $4.01 Direct F1
transaction GANX Restricted Stock Units Award $0 +13,200 $0.000000 13,200 15 Jul 2022 Common Stock 13,200 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest 25% on July 1, 2023 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F3 The RSUs shall vest 25% on July 1, 2023 and the remainder shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney